Edition:
United States

Trinity Biotech PLC (TRIB.OQ)

TRIB.OQ on NASDAQ Stock Exchange Global Select Market

5.63USD
12:19pm EST
Change (% chg)

$0.06 (+1.08%)
Prev Close
$5.57
Open
$5.59
Day's High
$5.74
Day's Low
$5.53
Volume
5,229
Avg. Vol
11,128
52-wk High
$7.21
52-wk Low
$4.30

Latest Key Developments (Source: Significant Developments)

Trinity Biotech reports Q3 earnings per share $0.063
Thursday, 26 Oct 2017 08:00am EDT 

Oct 26 (Reuters) - Trinity Biotech PLC :Trinity biotech announces results for Q3, 2017.Q3 earnings per share $0.063.Q3 revenue $25.6 million versus I/B/E/S view $26.1 million.  Full Article

Trinity Biotech Q2 earnings per share $0.068
Thursday, 20 Jul 2017 08:27am EDT 

July 20 (Reuters) - Trinity Biotech Plc ::Trinity Biotech announces results for Q2, 2017.Q2 earnings per share $0.068.Q2 revenue $25.4 million versus I/B/E/S view $25.5 million.Q2 earnings per share $0.031 excluding items.  Full Article

Trinity biotech Q1 earnings per share $0.05
Thursday, 27 Apr 2017 08:09am EDT 

April 27 (Reuters) - Trinity Biotech Plc :Trinity biotech announces results for q1, 2017.Q1 earnings per share $0.05.Q1 revenue $23.5 million.Q1 revenue view $24.3 million -- Thomson Reuters I/B/E/S.  Full Article

Lapides Asset Management LLC reports 5.1 pct passive stake in Trinity Biotech
Wednesday, 15 Mar 2017 11:13am EDT 

Trinity Biotech Plc :Lapides Asset Management LLC reports 5.1 percent passive stake in trinity Biotech Plc as of March 6 - sec filing.  Full Article

Trinity Biotech quarterly EPS $0.043
Tuesday, 14 Mar 2017 09:13am EDT 

Trinity Biotech Plc : Trinity biotech announces quarter 4 and fiscal year 2016 financial results . Quarterly earnings per share $0.043 . Q4 revenue $23.7 million versus i/b/e/s view $25.8 million . Trinity biotech plc - during quarter company recognised once-off charges amounting to $105.8 million net of tax .Trinity biotech plc - with closure of our swedish facility, going forward we will operate at close to a free cash flow break even position.  Full Article

Trinity Biotech announces withdrawal of Troponin FDA 510(k) submission
Tuesday, 4 Oct 2016 08:30am EDT 

Trinity Biotech Plc : Trinity biotech announces withdrawal of Troponin FDA 510(k) submission . FDA asked trinity to consider withdrawing their submission, due to some concerns they have about submission . To move technology from swedish facility to facility in ireland where it will be incorporated into research and development,manufacturing infrastructure . Moving of technology will result in closure of uppsala facility in sweden, which will result in approximately 40 redundancies . Trinity biotech announces withdrawal of troponin fda 510(k) submission . Held a meeting with fda on thursday 29 september, in order to obtain an update on company's meritas troponin submission . Fda asked trinity to consider withdrawing their submission, due to some concerns they have about submission . Fda's primary concerns relate to device's operating temperature range . "over coming weeks we will engage with fda to gain a better understanding of nature of their concerns" . Fda concerns also relate to troponin-i clinical performance not being consistent with clinical performance data .Will also recognise a non-cash write-off in excess of $50m, representing costs incurred on project, which will be recognised in q4.  Full Article

BRIEF-Trinity Biotech reports Q3 earnings per share $0.063

* Q3 revenue $25.6 million versus I/B/E/S view $26.1 million Source text for Eikon: Further company coverage: